MARKET

DBVT

DBVT

DBV Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.43
+0.14
+2.23%
After Hours: 6.43 0 0.00% 16:43 05/17 EDT
OPEN
6.36
PREV CLOSE
6.29
HIGH
6.54
LOW
6.35
VOLUME
127.33K
TURNOVER
--
52 WEEK HIGH
7.38
52 WEEK LOW
1.350
MARKET CAP
706.49M
P/E (TTM)
-4.3646
1D
5D
1M
3M
1Y
5Y
DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021
Montrouge, France, May 5, 2021 DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today annou...
GlobeNewswire · 05/05 21:10
10-Q: DBV TECHNOLOGIES S.A.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 05/05 20:18
64 Biggest Movers From Yesterday
Gainers
Benzinga · 05/05 09:59
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 05/04 16:00
VXRT, REGI, ARVL and CRNT among premarket gainers
BioLineRx BLRX +62% on positive top-line results from GENESIS phase 3 trial.Cocrystal Pharma (COCP) +40%.Huttig Building Products HBP +26% on Q1 results.Vaxart VXRT +20% as its oral COVID-19 vaccine shows potential to offer promising solution against
Seekingalpha · 05/04 12:19
26 Stocks Moving in Tuesday's Pre-Market Session
Gainers
Benzinga · 05/04 11:01
European ADRs Move Higher in Monday Trading
MT Newswires · 05/03 11:08
DBV Technologies Narrows Q1 Loss
MT Newswires · 05/03 07:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DBVT. Analyze the recent business situations of DBV Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DBVT stock price target is 9.67 with a high estimate of 17.01 and a low estimate of 2.001.
EPS
Institutional Holdings
Institutions: 91
Institutional Holdings: 37.14M
% Owned: 33.80%
Shares Outstanding: 109.87M
TypeInstitutionsShares
Increased
9
474.30K
New
11
795.82K
Decreased
9
681.61K
Sold Out
12
2.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.61%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Chief Executive Officer/Director
Pierre-Henri Benhamou
Chief Operating Officer
David Schilansky
Executive Vice President/General Counsel
Joan Schmidt
Chief Scientific Officer
Hugh Sampson
Vice President - Research & Development
Lucie Mondoulet
Vice President - Business Development
Nathalie Donne
Director of Marketing
Veronique Foutel
Other
Wence Agbotounou
Other
Bertrand Dupont
Other
Laurent Martin
Other
Pascale Ehouarn
Director
Michel de Rosen
Director
George Horner
Director
Mailys Ferrere
Director
Didier Hoch
Director
Chahra Louafi
Director
Rafaele Tordjman
No Data
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Webull offers kinds of DBV Technologies SA stock information, including NASDAQ:DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DBVT stock methods without spending real money on the virtual paper trading platform.